ES8406199A1 - Procedimiento para aislar un preparado inmunologicamente activo de glicoproteina gd-1 con envoltura de virus de herpes simplex de tipo 1. - Google Patents

Procedimiento para aislar un preparado inmunologicamente activo de glicoproteina gd-1 con envoltura de virus de herpes simplex de tipo 1.

Info

Publication number
ES8406199A1
ES8406199A1 ES519875A ES519875A ES8406199A1 ES 8406199 A1 ES8406199 A1 ES 8406199A1 ES 519875 A ES519875 A ES 519875A ES 519875 A ES519875 A ES 519875A ES 8406199 A1 ES8406199 A1 ES 8406199A1
Authority
ES
Spain
Prior art keywords
herpes simplex
simplex virus
materials
methods
monoclonal anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES519875A
Other languages
English (en)
Spanish (es)
Other versions
ES519875A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Patents Inc
Original Assignee
University Patents Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26996451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8406199(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University Patents Inc filed Critical University Patents Inc
Publication of ES8406199A1 publication Critical patent/ES8406199A1/es
Publication of ES519875A0 publication Critical patent/ES519875A0/es
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/224—Herpes related

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES519875A 1982-02-18 1983-02-17 Procedimiento para aislar un preparado inmunologicamente activo de glicoproteina gd-1 con envoltura de virus de herpes simplex de tipo 1. Granted ES519875A0 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35002182A 1982-02-18 1982-02-18
US06/463,141 US4762708A (en) 1982-02-18 1983-02-04 Materials and methods for herpes simplex virus vaccination

Publications (2)

Publication Number Publication Date
ES8406199A1 true ES8406199A1 (es) 1984-08-01
ES519875A0 ES519875A0 (es) 1984-08-01

Family

ID=26996451

Family Applications (1)

Application Number Title Priority Date Filing Date
ES519875A Granted ES519875A0 (es) 1982-02-18 1983-02-17 Procedimiento para aislar un preparado inmunologicamente activo de glicoproteina gd-1 con envoltura de virus de herpes simplex de tipo 1.

Country Status (20)

Country Link
US (1) US4762708A (enExample)
EP (1) EP0101506B1 (enExample)
JP (3) JP2665332B2 (enExample)
KR (1) KR910006889B1 (enExample)
AR (1) AR231496A1 (enExample)
AT (1) ATE54827T1 (enExample)
AU (1) AU554710B2 (enExample)
CA (1) CA1236774A (enExample)
DE (1) DE3381761D1 (enExample)
DK (1) DK172619B1 (enExample)
ES (1) ES519875A0 (enExample)
FI (2) FI73885C (enExample)
GR (1) GR77900B (enExample)
HU (1) HU195734B (enExample)
IE (1) IE56479B1 (enExample)
IL (5) IL80895A (enExample)
NO (2) NO162366B (enExample)
NZ (1) NZ220771A (enExample)
PH (1) PH25689A (enExample)
WO (1) WO1983002897A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540669A (en) * 1980-09-11 1985-09-10 Merck & Co., Inc. Herpes simplex type I subunit vaccine
US5149660A (en) * 1982-02-18 1992-09-22 University Patents, Inc. Diagnostic reagents relating to herpes simplex virus
NZ209307A (en) * 1983-08-30 1990-07-26 Genentech Inc Diagnostic product: antigenic peptide produced by recombinant dna techniques
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
JPS6051120A (ja) * 1983-08-31 1985-03-22 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニットワクチン
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
JPS6153226A (ja) * 1984-08-24 1986-03-17 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニツトワクチンの精製方法
DE3683688D1 (de) * 1985-04-19 1992-03-12 Wistar Inst Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
GB8605390D0 (en) * 1986-03-05 1986-04-09 Univ Birmingham Live herpes simplex vaccine
WO1990013652A1 (en) * 1989-05-12 1990-11-15 Triton Diagnostics, Inc. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5654174A (en) * 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
RU2146134C1 (ru) * 1999-06-29 2000-03-10 Ласкавый Владислав Николаевич Антивирусный препарат для инъекций
US20020090382A1 (en) * 2000-08-01 2002-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Antiviral compounds and methods
US20030219448A1 (en) * 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
ATE414176T1 (de) * 2002-07-18 2008-11-15 Univ Washington Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene
JP2007505147A (ja) * 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
AU2007292905B2 (en) * 2006-09-08 2013-05-23 The Trustees Of The University Of Pennsyvania HSV-1 and HSV-2 vaccines and methods of use thereof
US8865185B2 (en) * 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
US20130028925A1 (en) * 2006-12-28 2013-01-31 Harvey Friedman Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2008085486A1 (en) * 2006-12-28 2008-07-17 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US10478490B2 (en) * 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) * 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2011106607A2 (en) 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
CA2832738A1 (en) * 2011-04-08 2012-10-11 Duke University Herpes simplex virus
EA034351B1 (ru) 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374127A (en) * 1977-09-19 1983-02-15 Merck & Co., Inc. Herpes sub unit vaccine
IE53176B1 (en) * 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production

Also Published As

Publication number Publication date
NZ220771A (en) 1990-09-26
KR910006889B1 (ko) 1991-09-10
KR840003420A (ko) 1984-09-08
IL80896A0 (en) 1987-03-31
AR231496A1 (es) 1984-12-28
US4762708A (en) 1988-08-09
JPH0797396A (ja) 1995-04-11
JPH0769924A (ja) 1995-03-14
FI83880C (fi) 1991-09-10
FI833768A0 (fi) 1983-10-17
NO162366B (no) 1989-09-11
DE3381761D1 (de) 1990-08-30
GR77900B (enExample) 1984-09-25
FI73885C (fi) 1987-12-10
NO833773L (no) 1983-10-17
JP2567202B2 (ja) 1996-12-25
IL80895A (en) 1990-02-09
IL80896A (en) 1990-02-09
PH25689A (en) 1991-09-04
FI83880B (fi) 1991-05-31
CA1236774A (en) 1988-05-17
IL67930A (en) 1990-02-09
IE56479B1 (en) 1991-08-14
EP0101506B1 (en) 1990-07-25
AU554710B2 (en) 1986-08-28
EP0101506A4 (en) 1984-07-06
JP2669594B2 (ja) 1997-10-29
EP0101506A1 (en) 1984-02-29
ATE54827T1 (de) 1990-08-15
FI833768L (fi) 1983-10-17
AU1339683A (en) 1983-09-08
DK479083A (da) 1983-10-17
IL67930A0 (en) 1983-06-15
NO172745C (no) 1993-09-01
NO172745B (no) 1993-05-24
DK172619B1 (da) 1999-03-01
FI73885B (fi) 1987-08-31
WO1983002897A1 (en) 1983-09-01
JPS59500216A (ja) 1984-02-16
FI864102L (fi) 1986-10-10
JP2665332B2 (ja) 1997-10-22
ES519875A0 (es) 1984-08-01
IL80895A0 (en) 1987-03-31
IE830332L (en) 1983-08-18
DK479083D0 (da) 1983-10-17
FI864102A0 (fi) 1986-10-10
HU195734B (en) 1988-07-28
NO842962L (no) 1983-10-17

Similar Documents

Publication Publication Date Title
ES8406199A1 (es) Procedimiento para aislar un preparado inmunologicamente activo de glicoproteina gd-1 con envoltura de virus de herpes simplex de tipo 1.
Catalano et al. Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis.
KEEFER et al. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59
CA2123580A1 (en) Antigen of hybrid m protein and carrier for group a streptococcal vaccine
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
GR3030568T3 (en) Inducing cytotoxic t lymphocyte responses.
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
EP0200412A3 (en) Method of conferring immunotolerance to a specific antigen
RU94046145A (ru) Комбинированные вакцины, содержащие поверхностный антиген гепатита в и другие антигены, способ их получения, способ предупреждения инфекций гепатита в
NZ234586A (en) Peptide of a t-cell receptor capable of inducing protection from immune-related disease
ES2011334A6 (es) Metodo para la deteccion de anticuerpos de hiv-2.
IE900502L (en) Conjugates
AU1255383A (en) Foot and mouth disease viral antigenic peptides
EP0540645A4 (en) Methods of use of bovine respiratory syncytial virus recombinant dna, proteins vaccines, antibodies, and transformed cells
Morgan et al. Comparative immunogenicity studies on Epstein‐Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton‐top tamarins
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
EP0327180A3 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
IE881282L (en) Monoclonal antibodies to specific antigenic regions of the¹human immunodeficiency virus and methods for use.
Zweerink et al. Immune responses in mice against herpes simplex virus: mechanisms of protection against facial and ganglionic infections
GB2199038B (en) Immunologically active polypeptides useful for the preparation of antimalarial vaccines and of diagnostic kits for the detection of antisporozoite antibodies
IT1217314B (it) Nonapeptide sintetico ad attivita'adiuvante capace di potenziare in vivo la risposta anticorporale
DK257887D0 (da) Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden
AU554859B2 (en) Polymerized albumin vaccine
FI910587A0 (fi) Syntetiska polypeptider och antikroppar, vilka haenfoer sig till epstein-barr-virusets nukleaera antigen.
ATE175357T1 (de) Empfängnisverhütender impfstoff

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20041102